The Therapeutic Effects of Psychedelics: 2A or Not 2A?-Part 2
Some studies reveal that serotonin 2A receptor activation may not be necessary for the potential therapeutic effects of psychedelics.
Health
MDMA: A Catalyst for ED-PTSD Treatment
MDMA supplements treatment of co-occurring trauma and eating disorders
Fear of Death Impacts Quality of Life-How Psychedelics Can Help
Researchers suggest that the benefits of psychedelic treatment are mediated by a reduction in death anxiety and existential distress.
The Therapeutic Effects of Psychedelics: 2A or Not 2A? – Part 1
The serotonin 2A receptor is a major player in the psychedelic response, but it may not be the only one involved.
Glutamate’s Role in Rapidly-Acting Antidepressants
Despite differing pharmacodynamics, ketamine and serotonergic psychedelics may share downstream effects crucial to their rapid and sustained antidepressant activity.
Glow Time: PsychLight Brings a Powerful Tool to Psychedelic Research
This innovation may pave the way for pharmaceuticals that act like psychedelics at the 5-HT2A receptor but don’t have hallucinogenic effects.
Same But Different: Antidepressant Mechanisms of Psilocybin and Ketamine
Ketamine and psilocybin both exert rapid antidepressant effects. Could these effects be explained by a common mechanism that promotes neurogenesis?
Exploring the Role of Serotonin 2A Activation in LSD’s Effects on Empathy
A recent study indicates that the empathogenic effects of LSD may be independent of serotonin 2A receptor activation.
In Awe: Psychedelic Assisted Psychotherapy and the Mystical Experience
A fresh theoretical framework for understanding the role of awe in Psychedelic Assisted Psychotherapy.
Why Aren’t Psychedelic Drugs Prohibited in the 2021 Tokyo Olympics?
The truth is that scientists don’t know enough about them. And research into any athletic-enhancing capabilities they may have is lacking.